Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07785167 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Chemokine Receptors on CD8+ T Cells in Patients With Bipolar Disorder

Study acronym: SPERLIC
StatusNot Yet Recruiting
PhaseNot specified
Started2026-09-07
View on ClinicalTrials.gov ↗
This observational study investigates the expression profile of chemokine receptors and adhesion molecules in CD8+ T lymphocytes from individuals with Bipolar Disorder compared with healthy controls. The study focuses on CCR5 and CXCR3, which are involved in CD8+ T-cell migration toward the central nervous system, as well as the adhesion-related molecules PSGL-1, VLA-4, and LFA-1. Participants with Bipolar I or Bipolar II Disorder will be drug-naive or drug-free for at least 6 months and will be compared with healthy controls. Differences in molecular expression will also be explored according to the current mood episode, including depressive and manic/hypomanic phases. Gene expression will be assessed by real-time PCR in purified CD8+ T lymphocytes obtained from peripheral blood samples.
Trial Details
NCT Number NCT07785167
Lead Sponsor University of Catania
Conditions Bipolar Affective Disorders
Enrollment 172 participants
Start Date 2026-09-07
Primary Completion 2028-09-07 (estimated)
Study Completion 2028-09-07 (estimated)
Updated on ClinicalTrials.gov 2026-08-25